ViThera Pharmaceuticals, Inc
ViThera uses live biotherapeutics to treat diseases of the GI tract. Our lead product is for Crohn's Disease and Ulcerative Colitis.
ViThera's lead program (VT301) revolutionizes treatment for patients with Inflammatory Bowel Disease, a significant unmet need. Existing drugs target the immune system but VT301 heals the epithelial lining of the gut without affecting the immune system. ViThera's approach is validated by an early partnership with J & J. ViThera follows an aggressive path to clinical proof of concept (2015) and pursues early exit opportunities.